Galderma reported first-half 2026 net sales of $3.134 billion, up 24.6% year-over-year at constant currency, and raised full-year guidance. The driver: aesthetics revenue climbed 25%, fueled by patients on GLP-1 weight-loss medications seeking facial treatments to address volume loss and skin laxity—the so-called "Ozempic face" effect.
Business & M&A
Galderma Posts Record $3.1B H1 Sales, Raises Full-Year Guidance on GLP-1 Tailwinds
Aesthetics revenue surged 25% as weight-loss drug patients drive demand for facial rejuvenation.
Aesthetics revenue surged 25% as GLP-1 weight-loss drug patients drive demand for facial rejuvenation.
This is not a temporary blip. Galderma's CEO flagged the GLP-1 trend as a structural tailwind for the aesthetics category, particularly for volumizers and skin-tightening modalities. For practice owners, the implication is clear: patient demand for combination protocols—biostimulators like Radiesse or Sculptra paired with RF microneedling or thread lifts—will likely remain elevated. Galderma's portfolio (Restylane, Radiesse, Dysport) is positioned to capture this shift.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.